Regular follow-ups are necessary to monitor weight loss progress, adjust dosages as needed, manage side effects, and catch any early warning signs of complications such as gallbladder issues or pancreatitis
Research interest has focused on its possible role in telomere biology, telomerase activity, melatonin regulation, sleep quality, and age-related cellular processes
And the results of that trial were published last August (2017): Title: Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial Authors: Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T Journal: Lancet 2017 Aug 3
Collectively, these results suggest that cinchonine is a potential GLP-1R agonist
It is also not recommended for use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as semaglutide may increase the risk of these conditions
Very limited human data
